Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Project Updates and Milestones news
(page 17)
22 April 2026
OMV Petrom–RNV: three wind projects (~300 MW) enter execution phase
FID adopted; projects have permits and should begin staged production from H1 2027. Part of Oct 2024 deal; capacities: 50 MW, 100 MW, 155 MW. Separate 657 MW project awaiting FID.
22 April 2026
Rompetrol Rafinare’s Vega Ploieşti starts 60%‑purity hexane production
Unit optimizations enable higher‑purity hexane suited for oil extraction, adhesives, paints and degreasing; ~150 t/day capacity, boosts extraction yields and shortens processing time.
22 April 2026
Evonik expands biotech drug-substance capacity in Slovakia
€80M expansion adds downstream fermentation for drug‑substance manufacturing, creates ~50 jobs; follows rhamnolipids plant and boosts biotech scale‑up and sustainability.
22 April 2026
RWE and Polarium to market 50 MW / 135 MWh virtual battery via multi‑asset tolling
1,600+ behind-the-meter batteries are aggregated into a cloud-controlled virtual battery via multi-asset tolling, enabling market access and grid stability; target ~300MW/810MWh, 10k+ sites
21 April 2026
CATL unveils six battery innovations and integrated charge–swap network
Six batteries: Shenxing (10–15C); Qilin 280Wh/kg (1,000km) & Condensed 350Wh/kg (1,500km); Freevoy hybrid 230Wh/kg (600km); Naxtra Na‑ion GWh scale; charge–swap network, 4k stations.
21 April 2026
Nextchem unveils 100% recycled urban transport seat at Milano Design Week using NX Replast™
Collaborating with Italian design, post-consumer plastics are upcycled into high-performance recycled polymer meeting strength, durability and aesthetics, engineered for closed-loop reuse.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
21 April 2026
Roche’s fenebrutinib halves RMS relapse rate to ~1 per 17 years
FENhance 1/2: the BTK inhibitor cut MRI lesion activity vs teriflunomide and showed trends to less disability; PPMS trial non‑inferior to ocrelizumab. Safety: similar LFTs; more deaths.
21 April 2026
FDA approves Merck’s IDVYNSO (doravirine/islatravir)
Once-daily, tenofovir-free two-drug regimen approved for virologically suppressed adults; Phase 3 non-inferior to BIC/FTC/TAF. Contraindicated with strong CYP3A inducers or 3TC/FTC; skin reactions.
21 April 2026
Roche's ENSPRYNG cuts MOGAD relapse risk by 68%
Phase III METEOROID met primary endpoint in MOGAD: treatment cut relapses vs placebo, reduced MRI lesions and rescue therapy use, showed consistent safety; data to be filed with regulators
21 April 2026
EBA annual event: Europe shifts to industrial-scale battery execution
Panelists stressed transition from project launches to industrial ramp-up, needing coordinated policy, finance and market measures, new funding tools, and scalable tech to secure competitiveness
21 April 2026
Genentech Enspryng cuts MOGAD relapse risk 68% in Phase III
METEOROID met its primary endpoint: drug delayed first relapse vs placebo, with early response (~8w), lower relapse rate, fewer MRI lesions and rescue tx; safety consistent; filings planned
21 April 2026
Merck and Eisai: LITESPARK‑012 triplet regimens fail to improve PFS and OS versus KEYTRUDA+LENVIMA in first‑line RCC
Phase 3 LITESPARK‑012 tested pembrolizumab+lenvatinib+belzutifan and a pembrolizumab+quavonlimab+lenvatinib regimen; safety profiles consistent with prior studies; full analysis ongoing.
21 April 2026
Siemens expands Industrial Edge for enhanced data and AI integration
Industrial Edge: AI Suite & WinCC Unified GA. Management adds IEC62443 security and air‑gap. Information Hub gets bidirectional sync and ARM support. New machine‑vision and rugged HW partners.
21 April 2026
Arkema at Chinaplas 2026: high-performance materials
Showcases bio-based, recyclable high-performance polymers, additives and advanced materials for mobility, electronics, semiconductors and consumer goods; highlights Asia production expansions.
21 April 2026
LANXESS at IFAT 2026: Filtration for PFAS, Phosphorus, Micropollutants and UPW
IFAT showcase: ion‑exchange resins and adsorbents for regenerable phosphorus removal (Bayoxide E IN 20), PFAS and fluoride (MDS/TP resins), micropollutants (VP OC), and the LewaPlus design tool.
21 April 2026
Evonik opens expanded specialty-amine plant in Nanjing
Double-digit-million-euro expansion boosts specialty amine capacity in Nanjing, improving supply security, raw-material access and low-VOC additives for polyurethane/epoxy; plant runs on green power
21 April 2026
Evonik commissions 150 kV Antwerp substation
New 150 kV substation in Antwerp replaces 36 kV link, boosting capacity for industrial electrification and CO2 cuts; built with Elia, includes two 150t transformers and 6 ~1km cables.
21 April 2026
Statkraft completes Montes de Cierzo repowering with 98% waste recovery
44 ageing turbines replaced by 10 new units; capacity rises from 60 to 90 MW and output to 300 GWh/yr. 14.26 MW (28.51 MWh) batteries added. €5M local co-investment; full repower by 2027.
21 April 2026
ScottishPower and Masdar install UK’s largest 115m blades at East Anglia THREE
First turbine installed; 95×14MW units (1.4GW) with UK-made blades (285 in Hull). 262m tip height; will power ~1.3M homes. Installation using two jack‑up vessels.
21 April 2026
LKAB advances Luleå critical‑minerals demonstration plant
Installation underway at demo facility; building complete, commissioning autumn. Malmberget pilot tests the chain. Tech will extract phosphorus and 17 REEs from iron‑ore residues; permits ongoing.
21 April 2026
Axens, IFPEN and JEPLAN validate industrial-scale textile-to-textile polyester recycling
Semi-industrial test processed tens of tons of post-consumer polyester textiles to produce BHET monomer, validating textile-to-textile chemical recycling and enabling circular polyester loops.
21 April 2026
FDA accepts Roche sBLA for Gazyva/Gazyvaro in systemic lupus erythematosus (SLE)
ALLEGORY phase III: SRI‑4 response 76.7% vs 53.5% (adj diff 23.1%), doubled remission rates, fewer flares and reduced steroid use. FDA decision expected by Dec 2026.
21 April 2026
China Petrochemical’s next-generation green intelligent aromatics technology achieves international leading status
New aromatics tech validated: p-xylene adsorbent, ethylbenzene‑conversion isomerization catalyst, SMB single‑tower separation, intelligent control; 25 patents; +50% low‑temp heat reuse, −27% energy/unit
20 April 2026
FDA Accepts Genentech sBLA for Gazyva in SLE
FDA accepted sBLA for an anti‑CD20 in SLE after Phase III ALLEGORY: SRI‑4 responders 76.7% vs 53.5%, higher remission, fewer flares and steroid reduction; decision due Dec 2026.
20 April 2026
Topsoe to supply HydroFlex for Abundia's plastic-to-fuel facilities
Selected tech will convert plastic waste into drop-in diesel, sustainable aviation fuel and chemical feedstock at three North American plants (1,500 bpd each). Baytown FID end-2026; ops 2029.
20 April 2026
Elkem sells Saguenay biocarbon unit to CHAR Tech, secures 5‑year 62,500‑t supply
Sale transfers pilot/demo facility and proprietary pellet tech; site to be upgraded to 15,000 t/yr of pellets, converting raw biochar into biocarbon for ferrosilicon decarbonisation and smelter supply.
20 April 2026
Honeywell to support Dangote’s petrochemical expansion
Provide Oleflex tech to add 750,000 tpy propylene and petrochemical catalysts to produce 400,000 tpy linear alkylbenzene, boosting regional supply chains and industrial growth.
20 April 2026
Merck: FDA grants priority review for KEYTRUDA/KEYTRUDA QLEX with Padcev in cisplatin‑eligible MIBC
FDA granted priority review for two sBLAs after Phase 3 KEYNOTE‑B15 showed EFS and OS benefit; PDUFA Aug 17, 2026. If approved, first perioperative options for MIBC regardless of cisplatin eligibility.
20 April 2026
Perpetual Next hires GLS for U.S. biomethanol site selection
Consultant to assess U.S. candidate sites and feedstock markets, compare torrefaction, biomethanol and integrated concepts, and deliver evidence-based site-selection reports with risks and next steps.
20 April 2026
Novo Nordisk: Etavopivat meets phase‑3 HIBISCUS endpoints — reduces VOCs and increases haemoglobin in sickle cell disease
HIBISCUS phase‑3 (n=385, ≥12 yrs): etavopivat cut VOCs by 27% and delayed first VOC ~4 months; 48.7% had >1 g/dL Hb rise at 24 weeks vs 7.2% placebo. Well tolerated; filing H2 2026.
← Previous
Next →